Coronavirus COVID-19 Information
- Information for patients who have a scheduled test or appointment
- Information for hospital visitors
- Donations: How you can help
The administrative core provides financial, scientific, and technologic stewardship of the Cobre Center for Antimicrobial Resistance and Therapeutic Discovery (CARTD) at The Miriam Hospital. Core director Eleftherios Mylonakis, MD, PhD, FIDSA, and deputy director Gerard J. Nau, MD, PhD, establish overall program goals that are monitored by various committees and program staff at National Institute of General and Medical Sciences. Our overall mission is to foster an environment that inspires individuals to pursue laboratory science in antibiotic resistance and treatments by providing technical and mentoring support through our core facilities. We will pursue the following specific aims:
Core Director: Eleftherios Mylonakis, MD, PhD, FIDSA
Deputy Director: Gerard J. Nau, MD, PhD
Kerry LaPlante, PharmD, FCCP, FIDSA
Jason T Machan, PhD
Studies of antibiotic-resistant pathogens and new therapies must ultimately be evaluated in mammalian models of infection. These pre-clinical assessments are a fundamental step to determining whether new treatments might be translated to humans. Moreover, the complexities of the mammalian immune response can be queried in an animal model to gain insight into the basic pathobiology of infections and how the host affects the outcome of infections.
The animal models core of the CARTD will enable pre-clinical studies in mice to facilitate rapid, high-quality data acquisition. This core provides essential input to aid in experimental design that enhances the results. The core will maintain a portfolio of techniques directly related to the experimental objectives of the research projects, as well as diversify the research projects and to recruit investigators from outside the CARTD. The core’s design includes masking of treatment groups so that observers make unbiased assessments of the animals throughout the experiment. The core is responsible for managing the new in vivo imaging system that was recently procured by Lifespan. This system enhances the robustness and reproducibility of the studies by following up with individual animals and reducing the overall number of animals that are required in any given experiment. The animal models core’s functions are defined by the following specific aims:
PI: Gerard J. Nau, MD, PhD
The Biorepository Core for the CARTD is a source of well-characterized clinical isolates. Clinical isolates are microorganisms isolated from human specimens from which an infectious disease process is suspected. These microorganisms are essential for translational research projects focusing on antimicrobial drug resistance and therapeutic discovery.
The primary services of the biorepository core include:
PI: April M. Bobenchik, PhD, D(ABMM)